Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A. (December 2022)

• Record Type: Journal Article
• Authors: Iarossi, Michael; Lambert, Catherine; Hermans, Cedric
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 28(2022)
• Publication Date: 2022-12
• Subjects: Haemophilia A -- D-dimer -- thrombosis -- emicizumab -- anti-TFPI monoclonal antibody -- therapy targeting antithrombin.; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/10760296221143382
• Languages: English
• ISSNs: 1076-0296

Abstract

Background: The D-dimer (DD) assay is an essential biological test for the diagnosis and monitoring of thrombotic conditions. DD testing is usually not performed as part of the routine laboratory management of patients with hemophilia (PWH). There is an increasing concern about the risk of thrombotic complications in PWH, which is likely related to age, cardiovascular risk factors, invasive thrombogenic procedures, over-correction of Factor VIII (FVIII) or FIX, or administration of new therapeutic agents mimicking FVIII or rebalancing coagulation. Objective: This retrospective study sought to assess the basal DD levels in PWH treated prophylactically with FVIII, and to evaluate potential changes after switching to emicizumab. Method: Patients over 18 years of age treated with emicizumab within a single center over the period 2017-2022 were included in the study. Result: DD levels were measured in 40 adult PWH (37 severe/ three moderate / two with FVIII inhibitor) with a median age of 46 years (range: 19-82; Q1-Q3: 30, 25-56, 5), before and at least 3 months after emicizumab initiation. No significant changes were revealed, with DD median values of 257 ng/mL (range: 250-2876; Q1-Q3: 250-493, 5) before and 250 ng/mL (range: 50-6205; Q1-Q3: 250-380, 25) after the switch (p = 0.9). Conclusion: Most adult PWH on prophylaxis using FVIII display DD levels within the normal range, which remain unchanged after switching to emicizumab. In view of these reassuring results, monitoring of DDs at the start of emicizumab treatment does not appear necessary but could be considered when combined with other bypassing agents or high dose FVIII.